Alumis announces Phase 3 trial of envudeucitinib met all primary endpoints

Alumis (ALMS) announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis. Envudeucitinib met all primary and secondary endpoints with high statistical significance in ONWARD1 and ONWARD2. In each of these trials, envudeucitinib achieved superior skin clearance compared with placebo on the co-primary endpoints of Psoriasis Area and Severity Index, PASI, 75 and static Physician’s Global Assessment 0/1 at Week 16. On average across both ONWARD1 and ONWARD2, 74% of patients achieved PASI 75 and 59% of patients achieved sPGA 0/1, with responses deepening over time. In addition, the placebo-adjusted response rates for the co-primary endpoints were consistent between the two trials.